Work

AML-385 A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Year: 2024

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(24)01195-9

Authors: Harry P. Erba, Olalekan O. Oluwole, Dale Bixby, Raajit K. Rampal, Amir T. Fathi, Prashni Paliwal, Jin Jin, Ai Inoue, Naval Daver

Institutions: Duke Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, U-M Rogel Cancer Center, Memorial Sloan Kettering Cancer Center, Harvard University, Massachusetts General Hospital, Daiichi Sankyo (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401875798

Cites:

Cited by: 2

Related to: 10